ジェネリックがん無菌注射剤の世界市場レポート 2025年

ジェネリックがん無菌注射剤の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12.1％で301億7,000万米ドルに成長します。予測期間の成長は、ヘルスケア投資の増加、がん領域におけるバイオシミラーの採用、がん治療薬パイプラインの拡大、世界のがん罹患率の上昇、無菌注射剤のジェネリック医薬品に関する規制の流れなどに起因すると考えられます。予測期間における主な動向には、複雑なジェネリック腫瘍薬の開発、高度な製造技術の使用の増加、腫瘍学における個別化医療の台頭、バイオシミラー競争への重点の高まり、サプライチェーン管理におけるデジタル技術の統合などがあります。

がん罹患率の増加は、今後数年間のジェネリックがん無菌注射剤市場の成長を牽引すると予測されます。がんは、異常な細胞が制御不能に増殖し、正常な限界を超え、他の臓器への転移や隣接する身体部位への浸潤の可能性がある場合に、あらゆる臓器や組織に発生する可能性のある様々な疾患を包含します。がん患者の増加は、喫煙、放射線被曝、発がん物質、肥満、遺伝子変異などの要因によって促進されています。ジェネリックがん無菌注射剤製品は、腫瘍を縮小し、がん細胞の増殖を抑制するために利用されます。例えば、2024年4月、フランスを拠点とする研究機関である国際がん研究機関は、2022年に約2,000万人が新たにがんに罹患し、約1,000万人ががんに関連して死亡したと報告しました。予測によると、2050年には年間新規患者数は3,500万人に達し、2022年から77％増加する可能性があります。従って、がんの有病率の上昇ががん用無菌注射剤市場の成長を大きく牽引しています。

がん医療サービスに対する政府投資の増加は、今後のジェネリックがん無菌注射剤市場の成長を後押しすると予想されます。政府投資とは、特定の経済的、社会的、戦略的目標を達成するためのさまざまなプロジェクト、プログラム、イニシアチブに対する当局による公的資金の配分を指します。がん研究、治療施設、医療インフラに対する政府の資金援助が強化されることで、がん医療サービスへのアクセシビリティと質が向上します。例えば、2024年9月、英国に本部を置くがん研究機関Cancer Research UKは、2023/24会計年度に3億9,900万ポンドを割り当てた。この資金には、すべてのがん種にわたる研究に9,300万英ポンド、がんの基礎生物学の解明を目的とした基礎研究に8,400万英ポンドが含まれています。したがって、腫瘍学サービスに対する政府投資の増加は、がん無菌注射剤市場の成長を大きく後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のジェネリックがん無菌注射剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のジェネリックがん無菌注射剤市場：成長率分析
• 世界のジェネリックがん無菌注射剤市場の実績：規模と成長, 2019-2024
• 世界のジェネリックがん無菌注射剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界のジェネリックがん無菌注射剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のジェネリックがん無菌注射剤市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 代謝拮抗物質
• 植物アルカロイド
• 抗腫瘍抗生物質
• その他の製品
• 世界のジェネリックがん無菌注射剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のジェネリックがん無菌注射剤市場：疾患適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 卵巣がん
• 乳がん
• 肺がん
• 膵臓がん
• その他の適応症
• 世界のジェネリックがん無菌注射剤市場、タイプ別サブセグメンテーション：化学療法、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルキル化剤
• 代謝拮抗物質
• 有糸分裂阻害剤
• トポイソメラーゼ阻害剤
• 世界のジェネリックがん無菌注射剤市場、タイプ別サブセグメンテーション：代謝拮抗剤、実績と予測, 2019-2024, 2024-2029F, 2034F
• プリン類似体
• ピリミジン類似体
• 抗葉酸剤
• 世界のジェネリックがん無菌注射剤市場、タイプ別サブセグメンテーション：植物アルカロイド、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビンカアルカロイド
• タキサン
• カンプトテシン
• 世界のジェネリックがん無菌注射剤市場、タイプ別サブセグメンテーション：抗腫瘍抗生物質、実績と予測, 2019-2024, 2024-2029F, 2034F
• アントラサイクリン
• 非アントラサイクリン系抗生物質
• 世界のジェネリックがん無菌注射剤市場、タイプ別サブセグメンテーション：その他の製品、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的治療薬
• 免疫療法剤
• サポートケア製品

第7章 地域別・国別分析

• 世界のジェネリックがん無菌注射剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のジェネリックがん無菌注射剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ジェネリックがん無菌注射剤市場：競合情勢
• ジェネリックがん無菌注射剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline Plc
• Eli Lilly and Company
• Amgen Inc.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sandoz International GmbH
• Fresenius Kabi AG
• Sun Pharmaceutical Industries Inc.
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Cipla Inc.
• Hikma Pharmaceuticals plc
• Amneal Pharmaceuticals LLC
• Lupin Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ジェネリックがん無菌注射剤市場2029：新たな機会を提供する国
• ジェネリックがん無菌注射剤市場2029：新たな機会を提供するセグメント
• ジェネリックがん無菌注射剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A generic oncology sterile injectable is a biologic drug containing the same active ingredients as the branded version but differing only in the inactive components. It is utilized in the treatment of various cancer types, including breast, prostate, and colorectal cancers.

The primary products within the category of generic oncology sterile injectables include chemotherapy, antimetabolites, plant alkaloids, antitumor antibiotics, and other related medications. Chemotherapy, a type of treatment that employs potent chemicals to eliminate rapidly dividing cells in the body, is among the key components. These drugs are made available through diverse distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies. They are employed in the treatment of ovarian cancer, breast cancer, lung cancer, pancreatic cancer, and various other malignancies.

The generic oncology sterile injectable research report is one of a series of new reports from The Business Research Company that provides generic oncology sterile injectable market statistics, including the generic oncology sterile injectable industry's global market size, regional shares, competitors with generic oncology sterile injectable market share, detailed generic oncology sterile injectable market segments, market trends and opportunities, and any further data you may need to thrive in the generic oncology sterile injectable industry. This generic oncology sterile injectable market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The generic oncology sterile injectable market size has grown rapidly in recent years. It will grow from $17.17 billion in 2024 to $19.13 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to patent expirations for branded oncology drugs, increasing prevalence of cancer, growing focus on cost-effective healthcare solutions, regulatory support for generic medications, expansion of generic pharmaceutical companies

The generic oncology sterile injectable market size is expected to see rapid growth in the next few years. It will grow to $30.17 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing healthcare investments, adoption of biosimilars in oncology, expansion of oncology drug pipelines, rise in global cancer incidence, regulatory pathways for generic sterile injectables. Major trends in the forecast period include development of complex generic oncology drugs, increasing use of advanced manufacturing technologies, rise of personalized medicine in oncology, growing emphasis on biosimilar competition, integration of digital technologies in supply chain management.

The increasing prevalence of cancer is projected to drive the growth of the generic oncology sterile injectable market in the coming years. Cancer encompasses a range of diseases that can arise in any organ or tissue when abnormal cells multiply uncontrollably, exceed their normal limits, and potentially spread to other organs or invade adjacent body parts. The rise in cancer cases is fueled by factors such as smoking, radiation exposure, carcinogens, obesity, and genetic mutations. Generic oncology sterile injectable products are utilized to reduce tumors and inhibit the growth of cancer cells. For example, in April 2024, the International Agency for Research on Cancer, a France-based research organization, reported nearly 20 million new cancer cases and almost 10 million cancer-related deaths in 2022. Projections suggest that the annual number of new cases could reach 35 million by 2050, marking a 77% increase from 2022. Therefore, the rising prevalence of cancer is significantly driving the growth of the oncology sterile injectable market.

The rising government investments in oncology services are expected to boost the growth of the generic oncology sterile injectable market in the future. Government investments refer to the allocation of public funds by authorities toward various projects, programs, and initiatives to achieve specific economic, social, or strategic goals. Enhanced government funding for cancer research, treatment facilities, and healthcare infrastructure improves the accessibility and quality of oncology services. For instance, in September 2024, Cancer Research UK, a cancer research organization based in the UK, allocated £399 million for the 2023/24 financial year. This funding included £93 million for research across all cancer types and £84 million for basic research aimed at understanding the fundamental biology of cancer. Therefore, increasing government investments in oncology services are significantly driving the growth of the oncology sterile injectable market.

Product innovation is a prominent trend gaining traction in the generic oncology sterile injectable market. Leading companies in the sector are actively involved in developing innovative products to maintain their competitive edge. For example, in July 2022, Dr. Reddy's Laboratories, an India-based pharmaceutical company, introduced Bortezomib for injection, a generic version of Velcade. This injection, available in a single-dose vial with a dosage of 3.5 mg per 10 mL, is designed for intravenous or subcutaneous administration and is utilized in cancer treatment.

Leading companies in the generic oncology sterile injectable market are focusing on developing innovative medications, such as ready-to-use injectable (RTU) anti-nausea treatments, to improve patient care and enhance treatment outcomes. RTU anti-nausea treatments provide rapid relief from nausea, which helps enhance patients' overall treatment experiences and promotes adherence to chemotherapy regimens. For example, in September 2024, Amneal Pharmaceuticals, Inc., a US-based pharmaceutical company, launched focinveztm (fosaprepitant), a ready-to-use injectable aimed at preventing acute and delayed nausea and vomiting in adults and pediatric patients aged six months and older undergoing highly and moderately emetogenic chemotherapy. This product is free of Polysorbate 80 and requires no reconstitution or dilution, allowing for direct administration from its single-dose vial. This innovation is significant for the generic oncology sterile injectable market, as it provides a differentiated treatment option that improves pharmacy efficiency and includes a unique reimbursement code for chemotherapy patients.

In April 2022, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, completed the acquisition of Custopharm Inc. for $425 million. This strategic move is anticipated to enhance Hikma Pharmaceuticals' injectables business by incorporating a compelling portfolio of marketed products. Custopharm Inc. is a US-based company specializing in generic sterile injectables.

Major companies operating in the generic oncology sterile injectable market include Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Fresenius Kabi AG, Sun Pharmaceutical Industries Inc., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited, Zydus Lifesciences Limited, Nichi-Iko Pharmaceutical Co. Ltd., Biocon Ltd., Jubilant Pharmova Ltd., Gland Pharma Limited, Apotex Inc., Accord Healthcare Ltd.

North America was the largest region in the generic oncology sterile injectable market in 2024. Asia-Pacific is expected to be the generic oncology sterile injectable market report during the fastest-growing region in the forecast period. The regions covered in the generic oncology sterile injectable market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the generic oncology sterile injectable market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The generic oncology sterile injectable market consists of sales of paclitaxel injection, doxorubicin hydrochloride injection, and gemcitabine hydrochloride injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Generic Oncology Sterile Injectable Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on generic oncology sterile injectable market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for generic oncology sterile injectable ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The generic oncology sterile injectable market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Chemotherapy; Antimetabolites; Plant Alkaloids; Antitumor Antibiotics; Other Products
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By Disease Indication: Ovarian Cancer; Breast Cancer; Lung Cancer; Pancreatic Cancer; Other Indications
• Subsegments:
• 1) By Chemotherapy: Alkylating Agents; Antimetabolites; Mitotic Inhibitors; Topoisomerase Inhibitors
• 2) By Antimetabolites: Purine Analogs; Pyrimidine Analogs; Antifolates
• 3) By Plant Alkaloids: Vinca Alkaloids; Taxanes; Camptothecins
• 4) By Antitumor Antibiotics: Anthracyclines; Non-Anthracycline Antibiotics
• 5) By Other Products: Targeted Therapy Agents; Immunotherapy Agents; Supportive Care Products
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co Inc.; Sanofi S.A.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Generic Oncology Sterile Injectable Market Characteristics

3. Generic Oncology Sterile Injectable Market Trends And Strategies

4. Generic Oncology Sterile Injectable Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Generic Oncology Sterile Injectable Growth Analysis And Strategic Analysis Framework

• 5.1. Global Generic Oncology Sterile Injectable PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Generic Oncology Sterile Injectable Market Growth Rate Analysis
• 5.4. Global Generic Oncology Sterile Injectable Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Generic Oncology Sterile Injectable Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Generic Oncology Sterile Injectable Total Addressable Market (TAM)

6. Generic Oncology Sterile Injectable Market Segmentation

• 6.1. Global Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Antimetabolites
• Plant Alkaloids
• Antitumor Antibiotics
• Other Products
• 6.2. Global Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.3. Global Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ovarian Cancer
• Breast Cancer
• Lung Cancer
• Pancreatic Cancer
• Other Indications
• 6.4. Global Generic Oncology Sterile Injectable Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alkylating Agents
• Antimetabolites
• Mitotic Inhibitors
• Topoisomerase Inhibitors
• 6.5. Global Generic Oncology Sterile Injectable Market, Sub-Segmentation Of Antimetabolites, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Purine Analogs
• Pyrimidine Analogs
• Antifolates
• 6.6. Global Generic Oncology Sterile Injectable Market, Sub-Segmentation Of Plant Alkaloids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vinca Alkaloids
• Taxanes
• Camptothecins
• 6.7. Global Generic Oncology Sterile Injectable Market, Sub-Segmentation Of Antitumor Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anthracyclines
• Non-Anthracycline Antibiotics
• 6.8. Global Generic Oncology Sterile Injectable Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy Agents
• Immunotherapy Agents
• Supportive Care Products

7. Generic Oncology Sterile Injectable Market Regional And Country Analysis

• 7.1. Global Generic Oncology Sterile Injectable Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Generic Oncology Sterile Injectable Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Generic Oncology Sterile Injectable Market

• 8.1. Asia-Pacific Generic Oncology Sterile Injectable Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Generic Oncology Sterile Injectable Market

• 9.1. China Generic Oncology Sterile Injectable Market Overview
• 9.2. China Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Generic Oncology Sterile Injectable Market

• 10.1. India Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Generic Oncology Sterile Injectable Market

• 11.1. Japan Generic Oncology Sterile Injectable Market Overview
• 11.2. Japan Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Generic Oncology Sterile Injectable Market

• 12.1. Australia Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Generic Oncology Sterile Injectable Market

• 13.1. Indonesia Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Generic Oncology Sterile Injectable Market

• 14.1. South Korea Generic Oncology Sterile Injectable Market Overview
• 14.2. South Korea Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Generic Oncology Sterile Injectable Market

• 15.1. Western Europe Generic Oncology Sterile Injectable Market Overview
• 15.2. Western Europe Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Generic Oncology Sterile Injectable Market

• 16.1. UK Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Generic Oncology Sterile Injectable Market

• 17.1. Germany Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Generic Oncology Sterile Injectable Market

• 18.1. France Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Generic Oncology Sterile Injectable Market

• 19.1. Italy Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Generic Oncology Sterile Injectable Market

• 20.1. Spain Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Generic Oncology Sterile Injectable Market

• 21.1. Eastern Europe Generic Oncology Sterile Injectable Market Overview
• 21.2. Eastern Europe Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Generic Oncology Sterile Injectable Market

• 22.1. Russia Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Generic Oncology Sterile Injectable Market

• 23.1. North America Generic Oncology Sterile Injectable Market Overview
• 23.2. North America Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Generic Oncology Sterile Injectable Market

• 24.1. USA Generic Oncology Sterile Injectable Market Overview
• 24.2. USA Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Generic Oncology Sterile Injectable Market

• 25.1. Canada Generic Oncology Sterile Injectable Market Overview
• 25.2. Canada Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Generic Oncology Sterile Injectable Market

• 26.1. South America Generic Oncology Sterile Injectable Market Overview
• 26.2. South America Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Generic Oncology Sterile Injectable Market

• 27.1. Brazil Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Generic Oncology Sterile Injectable Market

• 28.1. Middle East Generic Oncology Sterile Injectable Market Overview
• 28.2. Middle East Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Generic Oncology Sterile Injectable Market

• 29.1. Africa Generic Oncology Sterile Injectable Market Overview
• 29.2. Africa Generic Oncology Sterile Injectable Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Generic Oncology Sterile Injectable Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Generic Oncology Sterile Injectable Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Generic Oncology Sterile Injectable Market Competitive Landscape And Company Profiles

• 30.1. Generic Oncology Sterile Injectable Market Competitive Landscape
• 30.2. Generic Oncology Sterile Injectable Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Generic Oncology Sterile Injectable Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline Plc
• 31.2. Eli Lilly and Company
• 31.3. Amgen Inc.
• 31.4. Baxter International Inc.
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Mylan N.V.
• 31.7. Sandoz International GmbH
• 31.8. Fresenius Kabi AG
• 31.9. Sun Pharmaceutical Industries Inc.
• 31.10. Dr. Reddy's Laboratories Ltd.
• 31.11. Aurobindo Pharma Limited
• 31.12. Cipla Inc.
• 31.13. Hikma Pharmaceuticals plc
• 31.14. Amneal Pharmaceuticals LLC
• 31.15. Lupin Limited

32. Global Generic Oncology Sterile Injectable Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Generic Oncology Sterile Injectable Market

34. Recent Developments In The Generic Oncology Sterile Injectable Market

35. Generic Oncology Sterile Injectable Market High Potential Countries, Segments and Strategies

• 35.1 Generic Oncology Sterile Injectable Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Generic Oncology Sterile Injectable Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Generic Oncology Sterile Injectable Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer